The two companies will undertake commercial activities using the Propeller clip-on sensor and software platform for use with GSK's ELLIPTA Inhaler.
The fully-integrated device delivers accurate doses to asthma and COPD patients, whilst providing on-screen instructions and feedback to the patient.
The funds will be used to expedite an FDA approval for the adult diagnostic test, expand into in-clinic use, and enter European and Asian markets.
Patients will have the opportunity to enroll in a new program to determine how Propeller's hi-tech tool can impact adherence rates and patient engagement.
Under the deal, Novartis will use Qualcomm Life's connectivity solutions to power its next-gen connected Breezhaler, the inhaler for its COPD portfolio.
The two companies have created the platform that combines adherence and lung function measurement with medication management services.
The company's connected devices and mobile apps engage and empower respiratory patients by measuring lung function and tracking adherence.
Available as a free download, the app relies on evidence-based care guidelines to empower COPD patients to better monitor and manage their condition.
The former is looking to use data for the early detection of arrhythmia and cerebral infarction, while the latter aims to collect data from people with COPD.
GSK will use the sensor in the studies to automatically collect and record data on the inhaler's usage, and wirelessly transmit the data collected.